| Drug Name |
Oritavancin |
| Drug ID |
BADD_D01623 |
| Description |
Oritavancin is a glycopeptide antibiotic used for the treatment of skin infections. It was developed by The Medicines Company (acquired by Novartis).[L12858] Oritavancin was initially approved by the FDA in 2014 and formulated to combat susceptible gram-positive bacteria that cause skin and skin structure infections. It boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy.[A39384,A193482,L8492]
On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion.[L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg. Marketed by Melinta Therapeutics, Kimyrsa offers effective and time-efficient treatment for skin and skin structure infections.[L32629] |
| Indications and Usage |
Oritavancin is indicated for the treatment of adult patients with acute bacterial skin and skin structure (including subcutaneous) infection. It is used for confirmed/suspected infections with designated and susceptible gram-positive organisms.[L8492] There are two preparations of oritavancin; the 400 mg dose that is administered over 3 hours, and the 1200 mg dose administered over 1 hour. Both are indicated for susceptible gram-positive skin and skin structure infections in adults.[L8492,L32629]
As antimicrobial susceptibility patterns are geographically distinct, local antibiograms should be consulted to ensure adequate coverage of relevant pathogens prior to use. |
| Marketing Status |
approved; investigational |
| ATC Code |
J01XA05 |
| DrugBank ID |
DB04911
|
| KEGG ID |
D05271
|
| MeSH ID |
C100708
|
| PubChem ID |
16136912
|
| TTD Drug ID |
D02IBU
|
| NDC Product Code |
70842-140; 68225-051 |
| UNII |
PUG62FRZ2E
|
| Synonyms |
oritavancin | LY 333328 | LY-333328 | LY333328 | Orbactiv |
